<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">clinvest</journal-id><journal-title-group><journal-title xml:lang="ru">Качественная клиническая практика</journal-title><trans-title-group xml:lang="en"><trans-title>Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2588-0519</issn><issn pub-type="epub">2618-8473</issn><publisher><publisher-name>ООО «Издательство ОКИ</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">clinvest-157</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРАКТИЧЕСКИЕ РЕКОМЕНДАЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRACTICAL RECOMMENDATIONS</subject></subj-group></article-categories><title-group><article-title>Современные аспекты фармакотерапии сахарного диабета 2 типа — фокус на ингибиторы ДПП-4</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скворцов</surname><given-names>В. В.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тумаренко</surname><given-names>А. В.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ГОУ ВПО «Волгоградский государственный медицинский университет», г. Волгоград</institution><country>Russian Federation</country></aff><aff xml:lang="ru" id="aff-2"><institution>ГБОУ ВПО «Волгоградский государственный медицинский университет» Минздравсоцразвития РФ, Волгоград</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>06</day><month>06</month><year>2018</year></pub-date><volume>0</volume><issue>1</issue><fpage>76</fpage><lpage>82</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Скворцов В.В., Тумаренко А.В., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Скворцов В.В., Тумаренко А.В.</copyright-holder><copyright-holder xml:lang="en">Скворцов В.В., Тумаренко А.В.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.clinvest.ru/jour/article/view/157">https://www.clinvest.ru/jour/article/view/157</self-uri><abstract><p>Описаны принципы лечения сахарного диабета 2 типа.</p></abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет 2 типа</kwd><kwd>ингибиторы ДПП-4</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">.Аметов А. С. Сахарный диабет 2 типа . Основы патогенеза и терапии . Москва, 2003 .</mixed-citation><mixed-citation xml:lang="en">.Аметов А. С. Сахарный диабет 2 типа . Основы патогенеза и терапии . Москва, 2003 .</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">.Аметов А.С., Демидова Т. Ю., Доскина Е. В., Черникова Н. А. Алгоритм диагностики и управления сахарным диабетом 2 типа . Клинические рекомендации для практикующих врачей . Москва, 2007 .</mixed-citation><mixed-citation xml:lang="en">.Аметов А.С., Демидова Т. Ю., Доскина Е. В., Черникова Н. А. Алгоритм диагностики и управления сахарным диабетом 2 типа . Клинические рекомендации для практикующих врачей . Москва, 2007 .</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">.Дедов И.И., Шестакова М. В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом . Москва, 2007 .</mixed-citation><mixed-citation xml:lang="en">.Дедов И.И., Шестакова М. В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом . Москва, 2007 .</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">.Fonseca V., at al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes . Diabetologia . 2007; 50:1148–1155 .</mixed-citation><mixed-citation xml:lang="en">.Fonseca V., at al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes . Diabetologia . 2007; 50:1148–1155 .</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">.Fonseca V., Dejager S., Albrecht S. et al. Vildagliptin as add–on to insulin in patients with type 2 diabetes (T2DM) . Diabetes 2006; 55 (suppl 1): A111 .</mixed-citation><mixed-citation xml:lang="en">.Fonseca V., Dejager S., Albrecht S. et al. Vildagliptin as add–on to insulin in patients with type 2 diabetes (T2DM) . Diabetes 2006; 55 (suppl 1): A111 .</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">.Garber A.G., et al. Efficacy and Tolerability of Vildagliptin Added to a Sulfonylurea in Patients with Type 2 Diabetes . Presented at ADA, 22–26 June 2007 (Abstract 501–P) .</mixed-citation><mixed-citation xml:lang="en">.Garber A.G., et al. Efficacy and Tolerability of Vildagliptin Added to a Sulfonylurea in Patients with Type 2 Diabetes . Presented at ADA, 22–26 June 2007 (Abstract 501–P) .</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">.Croxtall J.D., Keam S. J. Vildagliptin: a review of use in the management of type 2 diabetes mellitus . Drugs 2008; 68 (16): 2387–2409 .</mixed-citation><mixed-citation xml:lang="en">.Croxtall J.D., Keam S. J. Vildagliptin: a review of use in the management of type 2 diabetes mellitus . Drugs 2008; 68 (16): 2387–2409 .</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">.Halimi S., Schweizer A., Minic B. et al. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet . Vascular Health and Risk Management 2008; 4 (3): 481–492 .</mixed-citation><mixed-citation xml:lang="en">.Halimi S., Schweizer A., Minic B. et al. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet . Vascular Health and Risk Management 2008; 4 (3): 481–492 .</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">.Материалы сайтов health-ua.com, health-ua.org .</mixed-citation><mixed-citation xml:lang="en">.Материалы сайтов health-ua.com, health-ua.org .</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
